Results 131 to 140 of about 126,758 (293)
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
BackgroundCD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies. Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and ...
Xiaoshuang Yuan +13 more
doaj +1 more source
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the spondyloarthritis (SpA) spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede +11 more
wiley +1 more source
Funktionelle Charakterisierung Fc-optimierter CD19-gerichteter Antikörper [PDF]
Für Fc-vermittelte Effektormechanismen, wie die komplementabhängige Zytotoxizität (CDC) und die antikörperabhängige zellvermittelte Zytotoxizität (ADCC), konnte mit Daten aus zahlreichen Tiermodellen sowie klinische Studien die große Bedeutung für die ...
Roßkopf, Sophia Katharina
core
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Fouling‐Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing
ABSTRACT Lentiviral vectors (LVVs) are widely used as gene‐delivery vehicles in cell and gene therapy, enabling stable integration of transgenes into target cells. However, efficient clarification of LVV harvest remains a major bottleneck in large‐scale manufacturing, as conventional depth filtration often results in significant product loss.
Dohyun Park +5 more
wiley +1 more source
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source
Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue
ABSTRACT Archived patient samples (e.g., formalin‐fixed paraffin embedded (FFPE) tissue blocks, cryoembedded tissue blocks, and frozen whole tissue samples) are a source of immune information for which corresponding patient data is often collected.
Justin F. Tirados +5 more
wiley +1 more source
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley +1 more source

